TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral has given her Buy rating due to a combination of factors including Ovid Therapeutics’ promising pipeline and recent financial developments. The company’s Phase 1 study of OV329 demonstrated significant on-target activity and excellent safety, showing potential for treating drug-resistant epilepsies without the ocular toxicity associated with existing treatments like vigabatrin. This positive data supports the advancement of OV329 into a Phase 2a study, which is scheduled to begin in the second quarter of 2026.
Additionally, Ovid’s financial position appears robust with a cash runway extending into the early second half of 2026, bolstered by recent financing. The leadership transition, with Meg Alexander set to become CEO in January 2026, also suggests a strategic direction that may further enhance the company’s growth prospects. These elements combined provide a strong foundation for Ritu Baral’s optimistic outlook on Ovid Therapeutics, justifying the Buy rating.
Baral covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, ACADIA Pharmaceuticals, and Milestone Pharmaceuticals. According to TipRanks, Baral has an average return of 34.9% and a 56.94% success rate on recommended stocks.
In another report released today, Oppenheimer also downgraded the stock to a Buy with a $7.00 price target.